UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators

Free radical biology & medicine, 2013-09, Vol.62, p.52-64

2013

Volltextzugriff (PDF)

The therapeutic potential of monoamine oxidase inhibitors

Nature reviews. Neuroscience, 2006-04, Vol.7 (4), p.295-309

2006

Volltextzugriff (PDF)

Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases

Journal of Neural Transmission, 2018-11, Vol.125 (11), p.1719-1733

Youdim, Moussa B. H.

2018

Volltextzugriff (PDF)

The relevance of iron in the pathogenesis of Parkinson’s disease

Journal of neurochemistry, 2011-09, Vol.118 (6), p.939-957

2011

Volltextzugriff (PDF)

Iron, brain ageing and neurodegenerative disorders

Nature reviews. Neuroscience, 2004-11, Vol.5 (11), p.863-873

2004

Volltextzugriff (PDF)

Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment

Current drug targets, 2012-04, Vol.13 (4), p.483-494

2012

Volltextzugriff (PDF)

Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease

Frontiers in neuroscience, 2016-05, Vol.10, p.205-205

2016

Volltextzugriff (PDF)

Targeting Multiple Neurodegenerative Diseases Etiologies with Multimodal-Acting Green Tea Catechins

The Journal of nutrition, 2008-08, Vol.138 (8), p.1578S-1583S

2008

Volltextzugriff (PDF)

Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness

British journal of pharmacology, 2006-01, Vol.147 (S1), p.S287-S296

2006

Volltextzugriff (PDF)

Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases

The Journal of Nutritional Biochemistry, 2004-09, Vol.15 (9), p.506-516

2004

Volltextzugriff (PDF)

Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain

Neuroscience, 2011-08, Vol.189, p.345-358

2011

Volltextzugriff (PDF)

Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (‐)‐epigallocatechin‐3‐gallate: implications for neurodegenerative diseases

Journal of neurochemistry, 2004-03, Vol.88 (6), p.1555-1569

2004

Volltextzugriff (PDF)

Monoamine oxidase A upregulated by chronic intermittent hypoxia activates indoleamine 2,3-dioxygenase and neurodegeneration

PloS one, 2017-06, Vol.12 (6), p.e0177940-e0177940

2017

Volltextzugriff (PDF)

DJ‐1 deficiency triggers microglia sensitivity to dopamine toward a pro‐inflammatory phenotype that is attenuated by rasagiline

Journal of neurochemistry, 2014-05, Vol.129 (3), p.434-447

2014

Volltextzugriff (PDF)

Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities

Antioxidants & redox signaling, 2010-09, Vol.13 (6), p.919-949

2010

Volltextzugriff (PDF)

Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators

The FASEB journal, 2007-12, Vol.21 (14), p.3835-3844

2007

Volltextzugriff (PDF)

Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging

Neurobiology of aging, 2015-03, Vol.36 (3), p.1529-1542

2015

Volltextzugriff (PDF)

Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity

Progress in neurobiology, 2010-11, Vol.92 (3), p.330-344

2010

Volltextzugriff (PDF)

A sporadic Parkinson’s disease model via silencing of the ubiquitin–proteasome/E3 ligase component, SKP1A

Journal of Neural Transmission, 2024-06, Vol.131 (6), p.675-707

2024

Volltextzugriff (PDF)

Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis

The FASEB journal, 2009-11, Vol.23 (11), p.3766-3779

2009

Volltextzugriff (PDF)

M30 Antagonizes Indoleamine 2,3-Dioxygenase Activation and Neurodegeneration Induced by Corticosterone in the Hippocampus

PloS one, 2016-11, Vol.11 (11), p.e0166966-e0166966

2016

Volltextzugriff (PDF)

The Neuroprotective Activities of the Novel Multi-Target Iron-Chelators in Models of Alzheimer's Disease, Amyotrophic Lateral Sclerosis and Aging

Cells (Basel, Switzerland), 2023-02, Vol.12 (5), p.763

2023

Volltextzugriff (PDF)

neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline

Journal of neurochemistry, 2010-03, Vol.112 (5), p.1131-1137

2010

Volltextzugriff (PDF)

Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease

Journal of neurochemistry, 2007, Vol.100 (2), p.490-502

2007

Volltextzugriff (PDF)

The protective, rescue and therapeutic potential of multi-target iron-chelators for retinitis pigmentosa

Free radical biology & medicine, 2021-10, Vol.174, p.1-11

2021

Volltextzugriff (PDF)

1 – 25 von 1.443

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.266)
Mit Volltextzugriff
(892)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.438)
Japanisch
(160)
Deutsch
(4)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(888)
Life Sciences & Biomedicine
(877)
Animals
(720)
Neurosciences
(659)
Humans
(644)
Neurosciences & Neurology
(599)
Rats
(348)
Male
(336)
Biological And Medical Sciences
(220)
Monoamine Oxidase - Metabolism
(194)
Pharmacology & Pharmacy
(166)
Medical Sciences
(159)
Monoamine Oxidase Inhibitors - Pharmacology
(156)
Female
(143)
Biochemistry & Molecular Biology
(137)
Parkinson's Disease
(128)
Psychiatry
(128)
Neurology
(120)
Brain - Metabolism
(119)
Neuroprotective Agents - Pharmacology
(119)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators

The therapeutic potential of monoamine oxidase inhibitors

Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases

The relevance of iron in the pathogenesis of Parkinson’s disease

Iron, brain ageing and neurodegenerative disorders

Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment

Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease

Targeting Multiple Neurodegenerative Diseases Etiologies with Multimodal-Acting Green Tea Catechins

Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness

Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases

Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain

Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (‐)‐epigallocatechin‐3‐gallate: implications for neurodegenerative diseases

Monoamine oxidase A upregulated by chronic intermittent hypoxia activates indoleamine 2,3-dioxygenase and neurodegeneration

DJ‐1 deficiency triggers microglia sensitivity to dopamine toward a pro‐inflammatory phenotype that is attenuated by rasagiline

Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities

Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators

Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging

Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity

A sporadic Parkinson’s disease model via silencing of the ubiquitin–proteasome/E3 ligase component, SKP1A

Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis

M30 Antagonizes Indoleamine 2,3-Dioxygenase Activation and Neurodegeneration Induced by Corticosterone in the Hippocampus

The Neuroprotective Activities of the Novel Multi-Target Iron-Chelators in Models of Alzheimer's Disease, Amyotrophic Lateral Sclerosis and Aging

neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline

Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease

The protective, rescue and therapeutic potential of multi-target iron-chelators for retinitis pigmentosa

Suchergebnisse filtern